Novartis India share price
NSE: NOVARTINDBSE: 500672Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,824.50up ₹140.00 (8.31%)BSE ₹1,834.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,684.50.
52-week range of BSE trades to 23 Oct 2026
₹750.00Low, 21 Jan 2026₹2,588.00High, 10 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,505 Cr1,055th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 23 Jul 2026
- 46.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 5.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 23 Jul 2026
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 23 Jul 2026
- 12.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,46,21823.7% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 23 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹104 Crup 14.64%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹32 Crup 27.56%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 31.0%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Sep 2024Filed 7 Nov | Dec 2024Filed 28 Jan | Mar 2025Filed 23 Jun | Jun 2025Filed 29 Jul | Sep 2025Filed 28 Oct | Dec 2025Filed 28 Jan | Mar 2026Filed 12 May | Jun 2026Filed 23 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 |
| Net profit | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 23.4% | 27.4% | 34.9% | 31.5% | 26.8% | 18.7% | 27.9% | 31.0% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 73% of 2,433 trading days over the last 10 years.
LowestHighest
Its median29.0Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 99% of 1,965 trading days since Nov 2018.
LowestHighest
Its median2.5Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.37.7
At or below today's level on 66% of 1,837 trading days since May 2019.
LowestHighest
Its median30.2Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 3% of 2,456 trading days over the last 10 years.
LowestHighest
Its median1.58%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +23.7% | −7.7% | +33.9% | 0.0% |
| 3 years | +21.7% | −3.4% | +24.1% | 1.9% |
| 5 years | +15.1% | +34.9% | −17.0% | 3.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual funds holding it
8 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 3 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
- CutCut. Funds that held fewer shares than at the end of the month before.
- 1
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 3
| Fund | |||
|---|---|---|---|
 HDFC Pharma and Healthcare FundHDFC Mutual Fund | 1,00,627 | 0.55% | ₹19.3 Cr |
 Bandhan Healthcare FundBandhan Mutual Fund | 31,934 | 1.88% | ₹6.13 Cr |
| HDFC MNC FundHDFC Mutual Fund | 12,257 | 0.44% | ₹2.35 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 12,179 | 0.04% | ₹2.34 Cr |
 WhiteOak Capital Pharma and Healthcare FundWhiteOak Capital Mutual Fund | 11,712 | 0.24% | ₹2.25 Cr |
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 200 | 0.09% | ₹0.04 Cr |
| Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 94 | 0.09% | ₹0.02 Cr |
| Motilal Oswal BSE 1000 Index FundMotilal Oswal Mutual Fund | 21 | 0.01% | ₹40,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Novartis India in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sun Pharma Advanced Research CompanySPARC | 5,574 | 3.5 | 4.2 | 3.8 | +2,855.8% | – | 118.4% | 84.8% | 0.00% |
 FDCFDC | 5,514 | 18.8 | 2.2 | 16.3 | +3.4% | +8.7% | 12.3% | 11.1% | 1.48% |
 Orchid PharmaORCHPHARMA | 4,930 | – | – | – | +26.2% | – | – | 0.2% | 0.00% |
 IOL Chemicals and PharmaceuticalsIOLCP | 4,818 | 28.7 | 2.7 | 15.3 | +18.6% | +60.1% | 9.6% | 11.8% | 0.61% |
 RPG Life SciencesRPGLIFE | 4,333 | 36.3 | 7.2 | 27.0 | +11.8% | −34.6% | 21.0% | 21.3% | 0.92% |
 Zota Health CareZOTA | 4,304 | – | 6.2 | 1,419.0 | +78.9% | – | −22.5% | −12.8% | 0.08% |
 Gujarat Themis BiosynGUJTHEM | 4,217 | 86.6 | – | – | +17.5% | +9.2% | 18.2% | 15.1% | 0.21% |
 Gufic BiosciencesGUFICBIO | 3,929 | 53.5 | 5.9 | 25.7 | +16.7% | +18.7% | 11.6% | 12.7% | 0.03% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹47.50 a share, year to Mar 2023.
| Ex-date | Type | Per share |
|---|---|---|
| 23 Jul 2025 | Final | ₹25.00 |
| 23 Jul 2024 | Final | ₹25.00 |
| 20 Jul 2023 | Final | ₹10.00 |
| 20 Jul 2023 | Special | ₹37.50 |
| 20 Jul 2022 | Final | ₹10.00 |
| 17 Aug 2021 | Final | ₹10.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
8 Oct · Announcement under Regulation 30 (LODR)-Raising of Funds
8 Oct · Announcement under Regulation 30 (LODR)-Issue of Securities
5 Oct · Board meeting
Meeting on 8 Oct 2026: rights issue of equity shares
Novartis India share price by year
Each calendar year to 2025.Novartis India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 779.00 | −15.3% | 1,081.55 | 746.15 |
| 2024BSE close | 919.80 | +19.0% | 1,195.35 | 775.55 |
| 2023BSE close | 773.25 | +14.6% | 905.35 | 556.70 |
| 2022 | 674.55 | −13.1% | 789.45 | 573.85 |
| 2021 | 776.20 | +13.4% | 1,048.90 | 546.00 |
| 2020BSE close | 684.60 | +2.5% | 711.40 | 439.55 |
| 2019BSE close | 667.60 | −7.3% | 753.85 | 562.05 |
| 2018BSE close | 720.30 | +12.0% | 944.70 | 592.25 |
| 2017BSE close | 643.15 | −4.6% | 742.50 | 581.30 |
| 2016BSE close | 673.85 | −16.7% | 872.75 | 617.75 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,684.50 | 1,884.50 | 1,642.20 | 1,824.50 | 1,771.80 | 1,46,218 | 23.7% |
| 22 Oct 2026 | 1,770.00 | 1,813.80 | 1,665.00 | 1,684.50 | 1,725.10 | 55,386 | 39.3% |
| 21 Oct 2026 | 1,891.90 | 1,896.30 | 1,755.50 | 1,768.00 | 1,816.92 | 32,229 | 50.8% |
| 19 Oct 2026 | 1,888.10 | 1,940.00 | 1,869.70 | 1,921.60 | 1,906.25 | 12,000 | 49.6% |
| 16 Oct 2026 | 1,935.00 | 1,949.10 | 1,850.00 | 1,897.60 | 1,895.26 | 31,507 | 46.5% |
| 15 Oct 2026 | 1,985.00 | 1,985.00 | 1,923.40 | 1,940.10 | 1,946.60 | 22,385 | 54.2% |
| 14 Oct 2026 | 1,993.00 | 2,012.30 | 1,962.20 | 1,988.20 | 1,982.25 | 21,540 | 36.0% |
| 13 Oct 2026 | 2,002.20 | 2,035.00 | 1,940.00 | 1,991.60 | 1,979.52 | 43,896 | 60.8% |
| 12 Oct 2026 | 2,065.00 | 2,105.50 | 1,999.50 | 2,013.20 | 2,055.06 | 38,169 | 37.3% |
| 9 Oct 2026 | 1,997.60 | 2,095.00 | 1,943.10 | 2,049.00 | 2,007.43 | 49,497 | 34.5% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Buyback and offer for sale history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 26 Mar 2009 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Each event is noted and not adjusted for.
Company details
- Legal name
- Novartis India Limited
- NSE symbol
- NOVARTIND
- BSE code
- 500672
- ISIN
- INE234A01025
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1983
- Face value
- ₹5
- CIN
- L24200MH1947PLC006104
- Corporate identity number, the registrar of companies' code for it